Co-Diagnostics, Inc. operates as a molecular diagnostics company that develops, manufactures, and sells reagents used for diagnostic tests that function through the detection and/or analysis of nucleic acid molecules in the United States and internationally. It offers Co-Dx PCR platform, a polymerase chain reaction testing to patients in point-of-care and at-home setting. The company also provides PCR diagnostic tests for COVID-19, influenza, tuberculosis, hepatitis B and C, malaria, dengue, human papillomavirus, chikungunya, and Zika virus. In addition, the company offers three multiplexed tests to test mosquitos for the identification of diseases carried by the mosquitos; molecular tools for detection of infectious diseases; tests that identify genetic traits in plant and animal genomes; and portable diagnostic device designed to bring PCR to patients in point-of-care and at-home settings. Co-Diagnostics, Inc. was incorporated in 2013 and is based in Salt Lake City, Utah.…
Co-Diagnostics Announces Reverse Stock Split
Co-Diagnostics (NASDAQ: CODX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 115 employees.
The shares were at 0.1295 USD on 20 November 2026, down 98.9% over 52 weeks. Its 52-week range is 0.1276 USD to 13.54 USD: the price is 99.0% below the high and 1.5% above the low.
Its market capitalisation is 1.36M USD.
Co-Diagnostics reports return on equity of -227.3% and revenue up 94.6% year over year.
Its debt exceeds its cash by 849.70K USD, a debt-to-equity ratio of 0.06. Its Piotroski F-score is 1 out of 9, a weak reading of its financial health. The next earnings report is expected on 31 March 2027.